The company today reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate, MOD-6030. The study was set up to track the potential therapeutic effect of the drug when injected once weekly as measured by weight loss, reduction in food intake, glycemic control, and cholesterol levels. MOD-6030 is a long-acting version of oxyntomodulin, a naturally occurring hormone that acts as a natural signal to reduce food intake and increase energy expenditure following the ingestion of food.
In the study, MOD-6030 was administered to diet-induced obese mice once a week over a 30-day period. The results were that the drug showed significant efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity, and reducing cholesterol levels as compared to a control group that received a placebo. The mice receiving MOD-6030 achieved on average a 28% weight loss, a 29% reduction in food intake, a 19% drop in blood glucose levels, a 57% reduction in cholesterol levels, and a significant loss in body fat.
The study is great news for PROLOR Biotech. The company’s CEO Dr. Abraham Havron said, “We believe there is great demand among obese patients and their physicians for therapies that will help patients lose weight and reduce elevated glucose levels.”
For further information about PROLOR Biotech and all its potential drug candidates, please visit the company’s website at www.prolor-biotech.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
